Media OutReach
Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves
Strategic realignment powering Bora’s dual-engine businesses model
HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025.
Quarterly Business and Financial Highlights
- Company reported quarterly basic EPS of NT$5.09, with a loss per share of NT$1.49 from discontinued operations. Operating income reached NT$1,063 million and net income for continued operations came in at NT$822 million, resulting in quarterly EBITDA of NT$1,283 million, well on track to reclaim 2023 core P&L indicators.
- By the end of 3Q25, Bora’s operational integration and strategic streamlining efforts have been fully executed, meeting all targeted objectives. This milestone has led to a record-high CDMO business profitability, clear evidence that Bora’s dual-engine model is now entering its next phase of balanced but scalable growth.
- Fueled by expanded capacity and the addition of new dosage forms, Bora’s CDMO business grew 56.5% year-to-date through 3Q25, reaching over NT$7.3 billion and returning to a sequential growth trajectory.
- Pharma sales revenues fluctuated as legacy inventory phased out, and new products are still awaiting approvals. Generics portfolio competitiveness remains a key focus area in the near term. Led by Vigafyde, Bora’s rare disease portfolio continued to gain impressive market share with the vigabatrin franchise across three dosage forms continues. The Company targets to file its next specialty pharma product by year end to accelerate the rare neurology disease business. The Company also targets to market branded Deflazacort tablets by 2025 year end as a new driver for the business.
- The Company expects NTD to remain in the range of NTD 30-31 per USD for its operational planning.
- Share capital increased 19.99% during the quarter from stock dividend distribution, employee stock option exercise and convertible bond conversions.
- The Board approved Level-1 ADR issuance with each ADR share corresponding to 1/5 common share and total ADR issuance <10% of outstanding shares to enhanced market trust and investor service.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “Bora executed a record level of post-merger CAPEX investment in 2025 and we are progressing in line with our strategic plan. We have expanded our Maryland aseptic fill/finish capacity by approximately 10% while solid and liquid dosage capacity in Minneapolis and Mississauga grew around 3%. The investments allowed Bora to increase our operational efficiency and increase revenue per headcount in the CDMO business by ~30% during the quarter compared to beginning of the year.
The CDMO backlog rose to US$296 million, driven by 27 new contracts and over 20 new molecules year-to-date, providing solid visibility into 2026 with 72% commercialized projects. Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio, while paving the way for selective in-house manufacturing of specialty assets in the U.S.
As we look ahead, Bora is entering a phase of disciplined expansion and broader global recognition. Across our CDMO facilities in Asia and North America, we continue to actively navigate tariff and geopolitical challenges and turn them into new opportunities, strengthening supply chain resilience, and deepening collaboration with multinational partners.
On the pharma sales side, we continue to shed legacy low margin generics, increase our cashflow, and focus on our high-value generics pipeline, with certain PIV opportunities progressing to maturity in 2026. We remain dedicated on enhancing portfolio quality and increasing our Branded assets through selective specialty drugs, in order to build a more predictable and margin-accretive revenue base that mitigates product commoditization and price degredation.
In parallel, we are expanding our capital-market reach into the United States through the OTCQX Level-1 ADR program. We believe the Bora ADR will improve access and transparency for global institutional investors, while enabling overseas employees to participate in Bora’s growth. With no dilution and increasing visibility, we are laying the foundation for a stronger and more global 2026, defined by scaled growth, operational synergies, and increasing investor confidence.
3Q2025 Operational Achievements & Full Year Outlook
Global CDMO Operations
Global CDMO Operations (excluding intercompany orders from Upsher-Smith) revenues arrived at NT$1.78 billion in the third quarter and back to the sequential growth zone, representing approximately 37.13% of total revenue. A total of 418 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 33%. Year-to-date, CDMO revenues grew 18.98% over last year and reached NT$5.27 billion. Bora continues to execute on expanding this customer base to enhance business visibility and stability.
- As the Company ramps up its Maple Grove site, the momentum for U.S. manufacturing has been encouraging. Several clinical-stage clients are now transitioning into long-term strategic partnerships, with project scale and client size both increasing. Maple Grove is well positioned to be the Center of Excellence for scale-up and U.S. supply-chain integration for Bora.
- Large molecule CDMO operation revenues saw nearly 50% increase over the previous quarter, driven by one new ADC client and several change orders in addition to Cipla’s own labeled product launch under the collaboration agreement. Positioned as a one-stop CDMO platform alongside Bora Pharmaceuticals, Bora Biologics is now fully accelerating its CDMO operations
Pharma Sales Operations
Pharma Sales Operations in the third quarter reached a revenue of NT$3.02 billion, down 6.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 62.83% of total revenues.
- Discontinued loss per share (from the closure of the Plymouth production area) reflected the clearance sale of higher-cost inventories from Upsher-Smith’s legacy generics and internal supply transfer delayed by regulatory hurdles. These inventory clearance sales are now nearing completion. The greater-than-expected pricing pressure across our low margin generics reinforces the need to accelerate Bora’s transition toward higher-value and Branded specialty pharma products.
- The Vigabatrin franchise market share expansion continues with the “total patient” indicator seeing breakthrough in October.
- Bora continues to focus on DEE (Developmental and Epileptic Encephalopathies), where legacy compounds fail to meet significant unmet needs. The market is poised for new NCE entrants, expanding the addressable opportunity to roughly US$10 billion over the next 3–5 years. Bora aims to capture this growth through a Ready-to-Use 505(b)(2) pipeline and branded generics.
Recent Investor Conference
Bora will host an English online earnings call at 8:00 p.m. Taiwan time on Nov. 13th, 2025, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:30 p.m. on Nov. 14th, 2025. Both events will cover the company’s Q3’25 financial and business results and outlook.
English Online Earnings Presentation Link: https://events.q4inc.com/attendee/477519089
Bora will participate in the JP Morgan Healthcare Conference in January in San Francisco. For 1:1 meetings with management, please contact your JP Morgan representative.
Bora 2025 Earnings Schedule
Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit www.bora-corp.com.
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
When One Size Definitely Doesn’t Fit All
XIXILI’s Plus Size Collection flips the narrative that women need to settle for less-than-ideal sizes.
“For too many women, bra shopping has meant settling for sizes that almost fit or styles that prioritise function over fashion,” says XIXILI spokesperson Grace Tan. “Inclusivity is about recognising that every woman deserves access to beautiful, sexy, well-fitted lingerie. That shouldn’t be a problem they have to solve alone.”
To address the challenges of online fitting, XIXILI combines a detailed bra size chart with its pioneering ‘Try-On in 3D’ avatar tool. The feature allows women to generate a personalised digital twin based on specific measurements, enabling them to visualise the fit before purchasing.
Support Without Sacrifice: Plus Size Done Right
The Rufina Full Coverage Full Cup Bra sits at the heart of XIXILI’s Plus Size collection, designed for women who have been told they have to choose between support and style. The Rufina bra offers full coverage support with a contemporary silhouette that works under everything from work blouses to festive party dresses. Engineered specifically for fuller figures, it celebrates natural curves instead of trying to hide or minimise them. It’s the kind of foundation piece that lets you focus on your day, not your discomfort.
“We want every woman to feel supported, comfortable, and beautiful in whatever she’s wearing,” says Grace Tan. “Whether it’s for work, family gatherings, or special occasions, the right fit makes all the difference to daily comfort and confidence.”
Empowering Women With Knowledge, Not Just Options
XIXILI recognises that offering more sizes is only half the equation. Many women have spent years navigating limited options without proper guidance on finding their actual measurements.
The brand addresses this through interactive bra size charts, how-to-measure videos, and one-on-one personalised fittings at boutiques nationwide. By equipping women with the tools and knowledge to identify their true size, XIXILI transforms what can be a frustrating shopping experience into a more confident and informed process.
As Christmas shopping gets underway, the Plus Size Collection offers both a thoughtful gift for loved ones and an opportunity for self-care during the busy holiday season.
For more information and to discover the full range, visit XIXILI’s website.
Hashtag: #XIXILI
https://www.xixili-intimates.com/my/
https://www.facebook.com/XIXILI.OfficialFanPage/
https://www.instagram.com/xixili_intima/
https://www.tiktok.com/@xixili_intima?lang=en
https://www.youtube.com/user/xixilipage
The issuer is solely responsible for the content of this announcement.
XIXILI
A homegrown Malaysian brand, XIXILI offers beautiful fashion lingerie and shapewear in Malaysia that prioritises fit and comfort. With an extensive range of bra sizes from A to I and bands 65 to 110cm, XIXILI caters to women of all shapes and sizes. Expert fitters are dedicated to helping each customer find the perfect bra, boosting confidence and enhancing silhouettes.
XIXILI became the first Malaysian lingerie brand to introduce a Try-On in 3D avatar tool, allowing customers to virtually try on XIXILI lingerie using a 3D avatar tailored to their specific body type and measurements. Whether for everyday wear or something special, XIXILI ensures women always look and feel amazing.
Preparation Is Key
SIM reviews thousands of applications each year, and incomplete submissions remain one of the primary causes of processing delays. Early preparation of all required documents is essential to ensure a seamless application experience and allow applicants to remain focused on their academic objectives. As stipulated in SIM’s Application Process Guide, all supporting documents must be uploaded at the point of application and submissions lacking these documents will not be processed.
The Core Documents Every Applicant Needs
Prior to applying to the Singapore Institute of Management (SIM), applicants should ensure that all required documents are prepared to prevent processing delays. Scanned copies of academic certificates and transcripts, such as GCE ‘O’ and ‘A’ Levels, diplomas or degrees must be provided, along with certified translations and notarisation for documents not in English.
Proof of English language proficiency, such as IELTS or TOEFL results, is mandatory for applicants whose previous education was not conducted in English. Identification documents are also required, including the NRIC for local applicants and a valid passport for international applicants, accompanied by a recent passport-sized photograph that complies with SIM’s specifications.
International applicants must additionally prepare documentation for the Student’s Pass application, which includes the passport bio-data page, birth certificate, evidence of financial capability, and, where applicable, parent or guardian identification documents.
Quick Tips to Avoid Delays
Submitting an application to the SIM can be a straightforward process with proper preparation. Ensure that all documents are uploaded in the correct format, with PDF being the standard for certificates and transcripts. For documents not in English, certified translations must be provided to prevent rejection or requests for re-submission.
Applicants should also adhere to SIM’s photo specifications by submitting a recent passport-sized photograph that meets official guidelines. International students must pay particular attention to financial documentation, as proof of financial capability is a key requirement for the Student’s Pass application. Bank statements and supporting documents should be prepared in advance to comply with Immigration & Checkpoints Authority (ICA) requirements. Following these steps will help avoid unnecessary delays and ensure a smooth application process.
Application Essentials
Prospective students are advised to submit a complete and accurate application to ensure smooth processing. Detailed instructions and programme-specific requirements can be found on SIM’s official application portal. Applications that are incomplete or contain inaccuracies will not be considered. To avoid delays, applicants should make use of the provided checklist and guidelines to confirm compliance before submission.
References:
- SIM Application Process – https://www.sim.edu.sg/degrees-diplomas/admissions/application-process
Hashtag: #SIMGlobalEducation #SIMGE
The issuer is solely responsible for the content of this announcement.
About SIM Global Education
SIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor’s and master’s degree programmes with some of the world’s most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE’s cohort is made up of 16,000 full- and part-time students and adult learners, of which approximately 36% are international students hailing from over 50 countries.
SIM GE’s holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world.
For more information on SIM Global Education, visit sim.edu.sg
Media OutReach
Vinfuture 2025 Honors Four Groundbreaking Scientific Achievements Under The Theme “Rising And Thriving”
The 2025 VinFuture Prize Award Ceremony was broadcast live on VTV1, the national television channel of Vietnam. The event was attended by Mr. Tran Thanh Man, Politburo member and Chairman of the National Assembly, along with leaders of central ministries and agencies, representatives of embassies and international organisations, and distinguished scientists from around the world.
The VinFuture Prize 2025 received 1,705 nominations from scientists, research institutions, and technology enterprises worldwide, representing an almost threefold increase relative to the inaugural year. These submissions highlight impactful cross-border research efforts focused on protecting public health, advancing next-generation intelligent materials, addressing climate change, accelerating novel energy solutions, and strengthening global food security frameworks.
The 2025 VinFuture Grand Prize valued at US$3 million is awarded to Dr. Douglas R. Lowy, Dr. John T. Schiller, Dr. Aimée R. Kreimer and Prof. Maura L. Gillison (USA) for discoveries and development of HPV vaccines for prevention of tumors caused by human papillomaviruses.
Foundational studies on HPV capsid proteins by Drs. Douglas Lowy and John Schiller led to the development of highly effective HPV vaccines, preventing millions of cervical cancer cases, especially in developing countries. Furthermore, the single-dose vaccination regimen developed by Dr. Aimée Kreimer – now recommended by the World Health Organization (WHO) – has significantly expanded vaccine access for populations worldwide.
In parallel, laboratory and epidemiological studies by Prof. Maura Gillison and Dr. Aimée Kreimer established the link between HPV and head-and-neck cancers, which represent an emerging cancer threat expected to be mitigated by HPV vaccination efforts. The achievements of Dr. Douglas Lowy, Dr. John Schiller, Dr. Aimée Kreimer, and Prof. Maura Gillison have already saved millions of lives and will keep lowering the global cancer burden for decades to come.
In addition to the Grand Prize, the 2025 VinFuture Prizes will also present three Special Prizes, each valued at US$500,000, recognizing Innovators from Developing Countries, Women Innovators, and Innovators with Outstanding Achievements in Emerging Fields.
The 2025 VinFuture Special Prize for Innovators from Developing Countries is awarded to Prof. María Esperanza Martínez-Romero (Mexico) for advances in microbial ecology and symbiotic nitrogen fixation in the tropics. Prof. Martínez-Romero has discovered and described numerous new Rhizobium species, significantly expanding scientific understanding of microbial taxonomy and plant-microbe interactions in agriculture. Her work has opened new directions in the study of bacterial-plant symbiosis, with profound implications for sustainable agriculture in resource-limited settings.
The 2025 VinFuture Special Prize for Women Innovators is awarded to Prof. Mary-Claire King (USA) for identification of the breast and ovarian cancer susceptibility gene BRCA1, laying the foundation for genetic testing, screening programs, and personalized treatment. Her landmark identification of the BRCA1 locus on chromosome 17q21 in 1990, before the human genome was sequenced, is considered a historic milestone, demonstrating the genetic basis of cancer risk and transforming prevention and treatment strategies worldwide.
The 2025 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields has honored Prof. Venkatesan Sundaresan (USA), Prof. Raphaël Mercier (Germany), Dr. Emmanuel Guiderdoni (France), Dr. Imtiyaz Khanday (USA) and Dr. Delphine Mieulet (France) for innovations in the development of clonal hybrid crops. Hybrid seed production for rice, the staple food for more than half of humankind, is a laborious and costly procedure resulting in a high seed cost. The team’s work has enabled rice plants to produce seeds that retain all the superior traits of the parent plant through self-pollination, grounded in new insights into developmental biology and genetics. This groundbreaking research improves yields, reduces seed production costs, and advances sustainable global food security.
Sharing his reflections on this year’s honored works, Prof. Sir. Richard Friend, Chair of the VinFuture Prize Council, stated: “The 2025 VinFuture Prize Laureates have made big advances in science that have brought direct benefits to human health and to global sustainable food crop production. From new vaccines and new understanding of genetic susceptibility to disease to new approaches for plant breeding and new protocols for healthy crop growth, these achievements exemplify the power of science driven by compassion and cross-border collaboration – showing that when knowledge serves humanity, it not only deepens our understanding of the world but also strengthens and sustains the very foundations of life itself.”
After five consecutive and widely acclaimed award cycles, the VinFuture Prize has been securing recognition among the world’s most prestigious science and technology awards, receiving 6,132 nominations from nearly 110 countries and territories across five continents, and honoring 48 outstanding laureates. The awarded innovations—spanning clean energy, artificial intelligence, biomedical technologies, and transformative advances in agriculture—are elevating quality of life, strengthening human well-being, and shaping strategic pathways for the future of humanity.
The VinFuture Prize Ceremony and VinFuture Sci-Tech Week have evolved into an established global platform for scientific exchange, bringing together scientists, policymakers, and business leaders to advance collaborations toward a sustainable, humane, and prosperous future.
Notably, after five award seasons driven by persistent efforts to connect global scientific excellence with the Vietnamese research community, the VinFuture Foundation and the VinFuture Prize have not only fostered new opportunities and momentum for national science, but have also strengthened Vietnam’s standing as a trusted destination for the world’s scientific community—where innovation is widely shared and amplified for the collective prosperity of humankind.
Hashtag: #Vinfuture
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn